Suppr超能文献

儿童家庭肠外营养时的预防性抗凝。

Prophylactic anticoagulation in children receiving home parenteral nutrition.

机构信息

Pediatric Gastroenterology, Hepatology, and Nutrition, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Amsterdam UMC, University of Amsterdam, Amsterdam Reproduction and Development Research Institute, Amsterdam, the Netherlands.

出版信息

JPEN J Parenter Enteral Nutr. 2022 Jul;46(5):1036-1044. doi: 10.1002/jpen.2298. Epub 2021 Nov 18.

Abstract

BACKGROUND

Children with intestinal failure (IF) are at risk of loss of vascular access because of catheter-related venous thrombosis. Whether primary prophylactic anticoagulation is effective and safe in preventing catheter-related thrombosis is largely unknown. Our aim was to assess the incidences of catheter-related venous thrombosis and bleeding complications in children with IF receiving home parenteral nutrition (HPN) treated with primary prophylactic anticoagulation.

METHODS

All children, aged 0-18 years, treated with HPN at the Emma Children's Hospital/Amsterdam UMC were followed from January 2007 to July 2019. All patients were offered primary prophylactic anticoagulation from the start of HPN. The primary outcomes were catheter-related venous thrombosis and bleeding on prophylactic anticoagulation.

RESULTS

In total, 55 (76%) of 74 patients received primary prophylactic anticoagulation. The median age at the start of prophylaxis was 8.4 (interquartile range [IQR], 5.0-55.7) months. Patients were followed for a median of 31.2 (IQR, 10.7-53.5) months, with a total of 65,463 catheter days. The incidence of catheter-related thrombosis on prophylactic anticoagulation was 0.2 per 1000 catheter days. In total, the incidence of clinically relevant bleeding was 0.1 per 1000 catheter days. The median time to first event was 1268 (IQR, 149-2014) days for thrombosis and 389 (IQR, 227-2912) days for clinically relevant bleeding. Cumulative event-free survival after 5 years was 78% for thrombosis.

CONCLUSIONS

Our study shows a low rate of catheter-related venous thrombosis and a slightly elevated rate of clinically relevant bleeding in children receiving HPN and primary prophylactic anticoagulation.

摘要

背景

患有肠衰竭(IF)的儿童由于导管相关静脉血栓形成而存在血管通路丧失的风险。在预防导管相关血栓形成方面,初级预防抗凝是否有效和安全在很大程度上尚不清楚。我们的目的是评估接受家庭肠外营养(HPN)治疗的 IF 儿童中接受初级预防抗凝治疗的儿童的导管相关静脉血栓形成和出血并发症的发生率。

方法

所有在艾玛儿童医院/阿姆斯特丹 UMC 接受 HPN 治疗的 0-18 岁儿童均从 2007 年 1 月至 2019 年 7 月进行随访。所有患者在开始 HPN 时均接受初级预防抗凝治疗。主要结局是导管相关静脉血栓形成和预防性抗凝治疗时的出血。

结果

共有 74 例患者中的 55 例(76%)接受了初级预防抗凝治疗。开始预防治疗时的中位年龄为 8.4 岁(四分位距[IQR],5.0-55.7)。中位随访时间为 31.2 个月(IQR,10.7-53.5),总导管天数为 65,463 天。预防性抗凝治疗时导管相关血栓形成的发生率为每 1000 导管天 0.2 例。总共有 0.1 例临床相关出血的发生率为每 1000 导管天。血栓形成的首次事件中位时间为 1268 天(IQR,149-2014),临床相关出血的中位时间为 389 天(IQR,227-2912)。5 年后的血栓形成无事件生存率为 78%。

结论

我们的研究表明,接受 HPN 和初级预防抗凝治疗的儿童中,导管相关静脉血栓形成的发生率较低,而临床相关出血的发生率略高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验